Mersana Therapeutics Statistics
Total Valuation
MRSN has a market cap or net worth of $343.66 million. The enterprise value is $168.21 million.
| Market Cap | 343.66M |
| Enterprise Value | 168.21M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, before market open.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MRSN has 120.58 million shares outstanding. The number of shares has increased by 23.98% in one year.
| Shares Outstanding | 120.58M |
| Shares Change (YoY) | +23.98% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 1.33% |
| Owned by Institutions (%) | 95.21% |
| Float | 64.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.32 |
| Forward PS | 10.27 |
| PB Ratio | 9.31 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.91.
| Current Ratio | 3.36 |
| Quick Ratio | n/a |
| Debt / Equity | 0.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.15 |
Financial Efficiency
Return on equity (ROE) is -282.40% and return on invested capital (ROIC) is -254.72%.
| Return on Equity (ROE) | -282.40% |
| Return on Assets (ROA) | -62.60% |
| Return on Capital (ROIC) | -254.72% |
| Revenue Per Employee | $299,634 |
| Profits Per Employee | -$1.40M |
| Employee Count | 123 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.15% in the last 52 weeks. The beta is 1.51, so MRSN's price volatility has been higher than the market average.
| Beta (1Y) | 1.51 |
| 52-Week Price Change | -30.15% |
| 50-Day Moving Average | 4.39 |
| 200-Day Moving Average | 2.57 |
| Relative Strength Index (RSI) | 22.74 |
| Average Volume (30 Days) | 2,219,312 |
Short Selling Information
The latest short interest is 10.58 million, so 8.77% of the outstanding shares have been sold short.
| Short Interest | 10.58M |
| Short Previous Month | 10.13M |
| Short % of Shares Out | 8.77% |
| Short % of Float | 16.45% |
| Short Ratio (days to cover) | 5.08 |
Income Statement
In the last 12 months, MRSN had revenue of $36.86 million and -$171.67 million in losses. Loss per share was -$1.48.
| Revenue | 36.86M |
| Gross Profit | 36.86M |
| Operating Income | -179.67M |
| Pretax Income | -171.67M |
| Net Income | -171.67M |
| EBITDA | -163.30M |
| EBIT | -167.60M |
| Loss Per Share | -$1.48 |
Balance Sheet
The company has $209.08 million in cash and $33.63 million in debt, giving a net cash position of $175.45 million or $1.46 per share.
| Cash & Cash Equivalents | 209.08M |
| Total Debt | 33.63M |
| Net Cash | 175.45M |
| Net Cash Per Share | $1.46 |
| Equity / Book Value | 36.90M |
| Book Value Per Share | 0.31 |
| Working Capital | 150.42M |
Cash Flow
In the last 12 months, operating cash flow was -$168.88 million and capital expenditures -$2.17 million, giving a free cash flow of -$171.05 million.
| Operating Cash Flow | -168.88M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | -171.05M |
| FCF Per Share | -$1.47 |
Margins
Gross margin is 100.00%, with operating and profit margins of -487.51% and -465.80%.
| Gross Margin | 100.00% |
| Operating Margin | -487.51% |
| Pretax Margin | -465.80% |
| Profit Margin | -465.80% |
| EBITDA Margin | -443.09% |
| EBIT Margin | -454.75% |
| FCF Margin | -464.12% |
Dividends & Yields
MRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.98% |
| Shareholder Yield | -23.98% |
| Earnings Yield | -49.95% |
| FCF Yield | -49.77% |
Analyst Forecast
The average price target for MRSN is $5.57, which is 95.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.57 |
| Price Target Difference | 95.44% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 11.55% |
| EPS Growth Forecast (5Y) | -4.88% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MRSN has an Altman Z-Score of -5.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.51 |
| Piotroski F-Score | 3 |